Maxon Introduces Cinebench 2024
5.9.2023 16:06:00 EEST | Business Wire | Press release
Maxon, developers of professional software solutions for editors, filmmakers, motion designers, visual effects artists and creators of all types, is thrilled to announce the highly anticipated release of Cinebench 2024. This latest iteration of the industry-standard benchmarking software, which has been a cornerstone in computer performance evaluation for two decades, sets a new standard for performance evaluation, embracing cutting-edge technology to provide artists, designers, and creators with a more accurate and relevant representation of their hardware capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905630586/en/
Maxon Introduces Cinebench 2024: A New Standard for Performance Evaluation (Photo: Business Wire)
Redshift Rendering Engine Integration
Cinebench 2024 ushers in a new era by embracing the power of Redshift, Cinema 4D's default rendering engine. Unlike its predecessors, which utilized Cinema 4D's standard renderer, Cinebench 2024 utilizes the same render algorithms across both CPU and GPU implementations. This leap to the Redshift engine ensures that performance testing aligns seamlessly with the demands of modern creative workflows, delivering accurate and consistent results.
Dual Performance Evaluation: CPU and GPU
Cinebench 2024 reinstates GPU benchmarking, a feature absent from Cinebench for the past decade. The latest version not only evaluates CPU performance; it also provides insights into the GPU's capabilities, reflecting the evolving technological landscape of creative software and workflows.
Wider Platform Compatibility
Cinebench 2024 is designed to accommodate a broader range of hardware configurations. It seamlessly supports x86/64 architecture (Intel/AMD) on Windows and macOS, as well as Arm64 architecture to extend its reach to Apple silicon on macOS and Snapdragon® compute silicon on Windows, ensuring compatibility with the latest advancements in hardware technology. Redshift GPU performance can be evaluated on systems with compatible Nvidia, AMD and Apple graphics processors.
Unified Benchmarking Scene
Cinebench 2024 streamlines the benchmarking process by utilizing a consistent scene file for both CPU and GPU testing. This innovation enables users to discern the advantages of leveraging Redshift GPU, providing a real-world glimpse into the benefits of harnessing cutting-edge graphics hardware for rendering tasks.
Revamped User Interface
Cinebench 2024 introduces a revamped user interface that enhances the user experience and showcases the incredible artistic endeavors achieved with the Redshift render engine in Cinema 4D. This dynamic interface serves as a testament to the potential of the Redshift engine while offering users a more intuitive and visually engaging experience.
Under-the-Hood Enhancements
Beyond the surface, Cinebench 2024 brings forth a host of performance-enhancing features. With a threefold increase in memory footprint compared to Cinebench R23, the software caters to the memory-intensive demands of modern projects. Moreover, a six-fold rise in computational effort and utilization of newer instruction sets ensures a benchmark that resonates with the complexity and sophistication of contemporary creative projects.
Unparalleled Performance Evaluation
It's crucial to note that Cinebench 2024 scores cannot be directly compared to those of its predecessor, Cinebench R23. With the incorporation of Redshift, a different rendering engine, larger memory footprint, and more complex scenes, Cinebench 2024 offers a distinctly enhanced and accurate evaluation of modern hardware capabilities.
Availability
Cinebench 2024 is immediately available for download starting today on the official Maxon website. Creatives, gamers and technology enthusiasts are invited to explore this groundbreaking benchmarking tool and experience firsthand the leap in performance evaluation that it offers.
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.
Maxon’s team is composed of fun, passionate people who believe in building and empowering a successful artistic community. From our popular, inclusive events to our free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to our ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905630586/en/
Contact information
Press Contact
Chloe Larby
Grithaus Agency
(e) chloe@grithaus.agency
(p) +44 7454 012045
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom